Browsing Breast Cancer Research by publication type "Thesis or Dissertation"
Now showing items 1-20 of 21
-
Breast cancer and common malignancies in older adults
(Institute of Cancer Research (University Of London), 2022-08-08)Cancer is increasingly a diseases of older adults. However, they are heterogeneous and life expectancy and tolerance to stressors may vary greatly within this age group. Comorbidities, functional impairments, malnutrition, ... -
Capture Hi-C to identify regulatory variants and target genes influencing breast cancer risk
(Institute of Cancer Research (University Of London), 2022-10-26)Genome wide association studies have discovered approximately 200 breast cancer risk single nucleotide polymorphisms, most of which map to non-protein-coding regions. To understand the mechanisms influencing disease risk, ... -
Characterising transcriptomic and immune heterogeneity in aggressive invasive lobular breast cancers
(Institute of Cancer Research (University Of London), 2024-01-16)Invasive Lobular Carcinoma (ILC) is the second most common histological subtype of breast cancer (BC) accounting for 10-15% of all BCs. It is a unique disease entity with distinct histological appearances, molecular ... -
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ... -
Circulating tumour DNA analysis in advanced breast cancer
(Institute of Cancer Research (University Of London), 2022-10-17)Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the evolution of advanced breast cancer (ABC) and as a clinical tool to assist in ABC management. ctDNA analysis has not yet ... -
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ... -
Generating patient-derived models of soft-tissue sarcoma for the evaluation of therapy response and resistance
(Institute of Cancer Research (University Of London), 2023-05-04)For the majority of patients, advanced soft-tissue sarcoma (STS) is fatal, with an overall survival of 14-19 months. Systemic chemotherapy has remained the cornerstone of advanced STS control for more than 30 years and ... -
Genetic characterisation of radiation-induced breast cancer in survivors of Hodgkin's lymphoma
(Institute of Cancer Research (University Of London), 2019-08-31)Hodgkin's lymphoma (HL) accounts for less than one percent of new cancer cases every year in the UK. Although historically HL patients had a poor prognosis, decades of treatments for this hematopoietic neoplasm have led ... -
Identification of genetic determinants of ATR inhibitor sensitivity in ARID1A mutant ovarian clear cell carcinoma
(Institute of Cancer Research (University Of London), 2023-01-23)Ovarian clear cell carcinoma (OCCC) is a gynaecological cancer of unmet need characterized by ARID1A and PPP2R1A mutations. Prior work identified a synthetic lethality between ARID1A tumour suppressor mutations in OCCC and ... -
Identification of novel targets for the treatment of endocrine-resistant breast cancer
(Institute of Cancer Research (University Of London), 2022-05-31)While endocrine therapy is an effective, well-tolerated treatment for oestrogen receptor positive (ER-positive) breast cancer, a large proportion of initial responders will develop hormone therapy resistance, and relapse. ... -
Investigating a range of late effects of Hodgkin lymphoma treatments
(Institute of Cancer Research (University Of London), 2021-01-31)Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ... -
Investigation of combination treatments using radiotherapy and stimulators of nucleic-acid sensing immune pathways in an organoid model of basal-like breast cancer
(Institute of Cancer Research (University Of London), 2022-10-12)The majority of triple-negative breast cancers (TNBC) are of the basal-like subtype, which has a poorer prognosis than non-basal TNBC. Few targeted therapies are approved for TNBC, and although immune checkpoint inhibitors ... -
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ... -
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
(Institute of Cancer Research (University Of London), 2023-10-10)The PSMC3IP MND1 heterodimer promotes RAD51 and DMC1-dependent D loop formation during meiosis in yeast and mammalian organisms. For this purpose, it catalyses the DNA strand exchange activities of the recombinases. ... -
Modulation of the tumour immune microenvironment by cancer-associated fibroblasts
(Institute of Cancer Research (University Of London), 2019-11-30)The breast tumour microenvironment (TME) consists of a variety of non-cancerous cell types that can promote or inhibit cancer progression. Cancer-associated fibroblasts (CAFs) represent a major component of the breast TME ... -
Selective autophagy receptors in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)Pancreatic cancer accounted for 2.5% of all new cancers diagnosed worldwide in 2018, but remains disproportionally one of the most lethal cancers. Therefore, the development and validation of novel biomarkers (BMs), for ... -
Targeting Endo180 with an antibody-drug conjugate for cancer treatment
(Institute of Cancer Research (University Of London), 2024-03-22)Antibody-drug conjugates (ADCs) are formed of an antibody attached to a cytotoxic drug via a linker which is cleaved upon internalisation of the ADC into the cell. This allows very toxic drugs to be directed to specific ... -
Targeting RIPK1 ubiquitylation to promote anti-tumour immunity
(Institute of Cancer Research (University Of London), 2019-11-30)Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ... -
Targeting the tumour microenvironment with endosialin-directed CAR T-cells
(Institute of Cancer Research (University Of London), 2022-05-31)Advances in T-cell engineering have facilitated the generation of CAR T-cells that successfully deplete malignant cells of haematological cancers. However, attempts to target solid tumours with CAR T-cells have been hindered ... -
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...